Abstract. The dysregulation of cytoplasmic collapsin response mediator protein 1 (CRMP1) has been reported in lung cancer, medulloblastoma and esophageal cancer. However, the role of CRMP1 and its regulatory mechanisms in esophageal cancer remain unclear. In this study, we demonstrated that CRMP1 expression was downregulated in esophageal cancer tissues and that there were differences in its expression levels in different esophageal cancer cell lines. We found that CRMP1 overexpression inhibited the proliferation of esophageal cancer cells, whereas the silencing of CRMP1 promoted cell proliferation. We performed an analysis of potential microRNA (miRNA or miR) target sites using a commonly used prediction algorithm (TargetScan). The algorithm predicted that miR-200a-3p targets the 3' untranslated region (3'UTR) of CRMP1. Further experiments confirmed this prediction. In addition, we found that miR-200a-3p promoted the proliferation of esophageal cancer cells. Thus, our findings indicate that miR-200a-3p promotes the proliferation of human esophageal cancer cells by post-transcriptionally regulating CRMP1.
Introduction
Esophageal cancer (EC) is one of the six most common malignancies worldwide, with a higher incidence in males than in females (1) . The lifetime risk of developing this type of cancer is 0.8% for men and 0.3% for women. In addition, the risk increases with age, with a mean age at diagnosis of 67 years (2, 3) . EC is the seventh leading cause of cancer-related mortality among American males, particularly African American males, who have a higher incidence of this disease (13 cases per 100,000 individuals) than do males of other racial or ethnic origin (2, 4) . Elucidating molecular alterations in EC will help us to find new targets for effective therapies.
Cytoplasmic collapsin response mediator protein-1 (CRMP-1), also known as dihydropyrimidinase related protein-1 (DRP-1) is a brain-specific protein that belongs to the Unc-33-related protein family (5) (6) (7) . The dysregulation of cytoplasmic collapsin response mediator protein 1 (CRMP1) has been reported in brain, lung and pituitary tumors, and in EC (8) (9) (10) (11) . In prolactin-secreting pituitary adenoma, CRMP1 has been shown to be associated with tumor progression (12) . The downregulation of CRMP1 has been shown to be significantly associated with advanced disease, metastasis and shorter survival in non-small cell lung cancer (NSCLC), suggesting that CRMP1 acts as a novel tumor suppressor gene (13, 14) . Functional studies have demonstrated that the depletion of CRMP1 promotes tumor invasion, whereas its increased expression has an opposite effect in glioblastoma (9) . The expression level of CRMP1 has been shown to significantly correlate with the depth of invasion and lymph node metastasis in EC (11) . However, its role in EC has not yet been fully elucidated.
MicroRNAs (miRNAs or miRs) are a class of conservative single-stranded non-coding RNAs, composed of 17-25 ribonucleotides (15) . The deregulation of miRNA expression was previously detected in EC (16) . It was reported that the most markedly upregulated miRNAs were hsa-miR-15a, hsa-miR-28-3p, hsa-miR-31, hsa-miR-99b, hsa-miR-101, hsa-miR-130a, hsa-miR-143, hsa-miR-196b, hsa-miR-200a-3p, hsa-miR-210, hsa-miR-452 and hsa-miR-27a, whereas the most markedly downregulated miRNAs included hsa-miR-30b, hsa-miR-223, hsa-miR-454, hsa-miR-486, hsa-miR-574-3p and hsa-miR-126 in EC (16) . miRNAs are also involved in numerous physiological processes of cell regulation, including differentiation, proliferation, migration, invasion, apoptosis and metastasis (17) (18) (19) (20) .
In this study, we aimed to elucidate the role and regulatory mechanisms of CRMP1 in EC. We examined the effects of miR-200a-3p on EC. As we found that CRMP1 was a direct target of miR-200a-3p, we also examined the effects of CRMP1 on EC. Our data provide evidence that miR-200a-3p promotes the proliferation of EC cells by post-transcriptionally regulating CRMP1. 5'-GGTAGAAGGGATTTGTGCG-3'. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. The primers for GAPDH were as follows: forward, 5'-GAA GGTCGGAGTCAACGGATTTG-3'; and reverse, 5'-ATGGC ATGGACTGTGGTCATGAG-3'. PCR amplification was carried out under the following conditions: denaturation at 95˚C for 10 min, followed by 40 cycles of denaturation at 95˚C for 15 sec, annealing at 60˚C for 30 sec, and extension at 72˚C for 1 min. The relative expression level for target genes was normalized by the Ct value of GAPDH using the 2 -ΔΔCt relative quantification method.
qPCR for miRNA expression. The mirVana miRNA isolation kit (Ambion) was used to extract the total RNA from the cells according to manufacturer's instructions. Total RNA was used to generate cDNA using the specific RT-primer from the TaqMan gene expression assay kit (Applied Biosystems). qPCR was performed to determine the expression levels of miRNA. U6 was used as an internal control. The primer sequences were as follows: miR-200a-3p, 5'-UAACACUGUCUGGUAACGAUGU-3'; and U6, 5-'CGCTTCACGAATTTGCGTGTCAT-3' .
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
The effects on cell proliferation were assessed by MTT assay (Sigma, St. Louis, MO, USA) which was performed as previously described (21) . In brief, the cells were plated in 96-well plates in DMEM containing 10% fetal bovine serum at a density of 8x10 3 cells per well at 37˚C in a 5% CO 2 incubator for 12 h. The cells were transfected with the plasmids. MTT (5 mg/ ml) was then added to the wells (20 µl per well). The plates were then incubated in a cell incubator for 4 h, and the supernatant was then removed and 150 µl of dimethyl sulfoxide was added to each well. Following incubation for 10 min, the absorbance of each well was measured using a Synergy™ 4 (BioTek Instruments, Winooski, VT, USA) at a wavelength of 570 nm, with the reference wavelength set at 630 nm. The absorbance was directly proportional to the number of surviving cells.
In vitro proliferation assay. Cell proliferation was also assessed using a colorimetric BrdU proliferation kit according to the manufacturer's instructions (cat no. 74299; Roche, Indianapolis, IN, USA). The cells were incubated with BrdU for 3 h and wased with phosphate-buffered saline (PBS). The genomic DNA was fixed in 4% paraformaldehyde, immunolabeled for BrdU, and counterstained with the fluorescent nuclear marker, DAPI (Sigma).
Cell cycle analysis. The cells (8.0x10
5 cells) were seeded into a 100-mm culture plate and allowed to attach overnight. The cells were transfected with the plasmids for 24 h, washed twice with NaCl/Pi, and then centrifuged at 200 x g at room temperature. The pellet was resuspended in 1 ml cold NaCl/Pi and fixed in 70% ethanol for at least 12 h at 4˚C. The fixed cells were incubated with 100 µl DNase-free RNase A (200 µg/ml) for 30 min at 37˚C, and then 1 mg/ml propidium iodide was added. The stained cells were analyzed using a fluorescence-activated cell sorter (BD Accuri C6; BD Biosciences, Ann Arbor, MI, USA). The percentages of cells in the G1, S and G2/M phases of the cell cycle were determined using CellQuest Pro software (FlowJo, Ashland, OR, USA).
Bioinformatics analysis. The analysis of potential miRNA target sites was carried out using the commonly used prediction algorithm, TargetScan (http://www.targetscan.org). Statistics analysis. Data are presented as the means ± SE, and are the product of 3 independent experiments. Significance among the groups was determined using a Student's t-test. Statistical significance was set at P<0.05.
Results

CRMP1 is downregulated in EC and CRMP1 expression differs between different EC cell lines.
In an aim to identify differences in CRMP1 expression between EC tissues and adjacent normal tissues, we performed western blot analysis. Protein was isolated from 6 pairs of EC tissues and normal tissues (patient nos. 1-6). We found that CRMP1 protein expression was significantly decreased in the tumor tissues, compared with the adjacent normal tissues (Fig. 1A) . This suggested that CRMP1 may be a tumor suppressor gene in EC. In order to examine CRMP1 protein expression among different EC cell lines, we performed western blot analysis using 6 EC cell lines (TE1, TE2, TE3, TE4, TE5 and TE6 cells). Protein isolated from the 6 EC cell lines was examined and the results revealed that CRMP1 expression differed betwee the different EC cells (Fig. 1B) . Specifically, CRMP1 expression was lowest in the TE3 cells and highest in the TE1 cells. However, for our further experiments, we selected the TE2 cells.
CRMP1 inhibits the proliferation of TE2 EC cells.
To examine whether CRMP1 affects the proliferation of EC cells, firstly, by using western blot analysis, we examined whether a CRMP1-expressing plasmid can be used to stably express CRMP1 protein in TE2 cells. The results revealed that CRMP1 protein expression was significantly increased by transfection of the cells with the CRMP1-expressing plasmid ( Fig. 2A) . In addition, we performed MTT assay to examine the proliferation of TE2 cells transfected with the CRMP1-expressing plasmid. The results revealed that the overexpression of CRMP1 inhibited the proliferation of TE2 cells after 48 h of transfection (Fig. 2B) . To examine the effects of CRMP1 on cell proliferation, we also performed cell cycle analysis to examine its effects on the cell cycle. The results revealed lower S phase and G2 phase fractions in the TE2 cells transfected with the CRMP1-overexpressing plamid than in the cells transfected with the empty vector (Fig. 2C) . To identify whether DNA synthesis inhibition contributes to the lower S phase fractions in the TE2 cells transfected with the CRMP1-overexpressing plamid, we performed a BrdU incorporation assay to detect DNA synthesis in the cells. The results confirmed that CRMP1 significantly inhibited DNA synthesis in the cells (Fig. 2D) . In addition, we also performed western blot analysis to further confirm that CRMP1 affects proliferation markers. The results of western blot analysis demonstrated that CDK4 expression was downregulated and the expression of p53 and p21 was upregulated by the overexpression of CRMP1 (Fig. 2E) .
Silencing of CRMP1 promotes the proliferation in of TE2 EC cells.
In an attempt to further identify the role of CRMP1 in regulating proliferation of TE2 cells, the cells were transfected with a shCRMP1 plasmid. Following stable transfection, CRMP1 protein expression was detected by western blot anal- ysis. The results revealed that transfection with the shCRMP1 plasmid evidently suppressed CRMP1 protein expression in the TE2 cells (Fig. 3A) . Moreover, the proliferation rates of the TE2 cells were examined by MTT assay. The results revealed that the silencing of CRMP1 promoted the proliferation of the TE2 cells (Fig. 3B ). This was confirmed by BrdU incorporation assay, which indicated that transfection with the shCRMP1 plasmid resulted in increased DNA synthesis activity per viable cell in the cells (Fig. 3C) . To further confirm that CRMP1 regulates the proliferation of TE2 cells, we performed western blot analysis to detect the expression of proliferation markers (CDK4, p53 and p21). The results demonstrated that CDK4 expression was upregulated, and that of p53 and p21 was downregulated in the cells transfected with the shCRMP1 plasmid (Fig. 3D) . The above-mentioned findings demonstrated that the silencing of CRMP1 promoted the proliferation of TE2 cells.
miR-200a-3p suppresses CRMP1 protein expression in TE2
EC cells. miRNAs/miRs are a class of non-coding RNAs able to regulate gene expression at the post-transcriptional level, by binding to the 3'UTR of target messenger RNAs (mRNAs) through partial sequence homology, and causing a block of translation and/or mRNA degradation (22-24) . The upregulation of specific miRNAs can contribute to the downregulation of tumor suppressor genes (25) (26) (27) . Thus, we hypothesized that CRMP1 is downregulated by miRNAs in EC.
We screened for miRNAs targeting CRMP1 using TargetScan (http://www.targetscan.org/), and a large number of target miRNAs were found. However, we were interested in miR-200a-3p, as it has been previously shown to be upregulated in EC (16) . The target sites on the 3'UTR of CRMP1 are shown in Fig. 4A . We hypothesized that miR-200a-3p downregulates CRMP1 expression by targeting its 3'UTR in EC cells.
In order to determine whether CRMP1 is downregulated by miR-200a-3p in EC, we transfected the TE2 EC cells with pre-miR-200a-3p and qPCR was then performed to detect miR-200a-3p expression in the cells. The results revealed that transfection with pre-miR-200a-3p significantly upregulated miR-200a-3p expression (Fig. 4B) . To determine whether CRMP1 protein expression is affected by miR-200a-3p, we performed immunofluorescence analyses. The results of immunofluorescence analyses revealed that CRMP1 protein expression was significantly downregulated by transfection with pre-miR-200a-3p in the TE2 cells (Fig. 4C) . Moreover, western blot analysis was performed to detect CRMP1 protein expression in TE2 cells transfected with pre-miR-200a-3p. Consistent with the results of immunofluorescence analyses, we found that CRMP1 protein expression was significantly downregulated by transfection with pre-miR-200a-3p in TE2 cells (Fig. 4D) . To determine whether CRMP1 mRNA expression was decreased by miR-200a-3p, we then performed RT-PCR and qPCR to detect CRMP1 mRNA expression in TE2 cells transfected with pre-miR-200a-3p or control miR. The results of RT-PCR and qPCR demonstrated that miR-200a-3p did not affect CRMP1 mRNA expression in TE2 cells (Fig. 4E and F) .
miR-200a-3p promotes the proliferation of TE2 EC cells.
In an attempt to identify the role of miR-200a-3p in regulating the proliferation of TE2 cells, the cells were transfected with pre-miR-200a-3p. Following transfection, the proliferation rates of TE2 cells were examined by MTT assay. The results revealed that transfection with miR-200a-3p promoted the proliferation of TE2 cells (Fig. 5A) . This was further revealed by BrdU incorporation assay which indicated that transfection with pre-miR-200a-3p resulted in increased DNA synthesis activity per viable cell (Fig. 5B) . To further confirm that miR-200a-3p can regulate EC cell proliferation, we performed western blot analysis to detect the expression of proliferation markers (CDK4, p53 and p21). The results revealed that CDK4 expression was upregulated, and that of p53 and p21 was downregulated in the cells transfected with pre-miR-200a-3p (Fig. 5C) . The above-mentioned findings demonstrated that miR-200a-3p promoted the proliferation of TE2 cells.
Discussion
EC is one of the six most common malignancies worldwide and is associated with a 5-year survival rate >25% (1) . Understanding the molecular biology of the disease is a prerequisite to predicting prognosis and to selecting effective treatment options. The development of EC is a multistep phenomenon involving genetic events that result in key abnormalities of cell cycle regulation, growth factor activity and intercellular adhesion mechanisms (28) .
Consistent with previous findings demonstrating that CRMP1 significantly inhibited the proliferation of medulloblastoma cells (29), we found that its overexpression also inhibited the proliferation of EC cells. It has been demonstrated that CRMP1 significantly inhibits the migration, invasion of and the formation of filopodia and intense stress fibers in medulloblastoma cells (29) . In addition, the expression level of CRMP1 has been shown to significantly correlate with the depth of invasion and lymph node metastasis in EC (11) . In the future, we aim to determine whether CRMP1 affects the migration and invasion of TE2 EC cells.
The p53 tumor suppressor lies at a nexus of cellular pathways that sense DNA damage, cellular stress and improper mitogenic stimulation (30) . p53 integrates such signals and, in response, induces growth arrest, promotes apoptosis, blocks angiogenesis, or mediates DNA repair in a context-dependent manner (31) . The importance of p53 in preventing tumor formation is indicated by the presence of mutations in the p53 pathway in almost all types of cancer (32) . In this study, we found that CRMP1 overexpression significantly upregulated p53 protein expression and the silencing of CRMP1 downregulated p53 protein expression in TE2 EC cells. p21-mediated growth inhibition has been attributed to two main activities that depend on two non-overlapping structural domains: the carboxy-terminal PCNA-binding domain and the amino-terminal CDK-cyclin inhibitory domain (33, 34) . By binding to PCNA, p21 competes for PCNA binding with DNA polymerase-δ and several other proteins involved in DNA synthesis, thus directly inhibiting DNA synthesis (35) . We demonstrated that CRMP1 overexpression significantly upregulated p21 protein expression and the silencing of CRMP1 downregulated p21 protein expression in TE2 EC cells. Our results suggeswt that CRMP1 functions as a tumor suppressor gene by regulating p21 and p53 in EC.
As recently demonstrated through miRNA microarray analysis, miR-200 is upregulated in nasopharyngeal carcinoma (NPC). It was also shown that the endogenous miR-200a-3p expression level increases with the degree of differentiation in a panel of NPC cell lines, and that the overexpression of miR-200a-3p inhibits C666-1 cell growth, migration and invasion, whereas its knockdown stimulates these processes in CNE-1 cells (36) . However, the role of miR-200a-3p remains unclear in EC. In this study, we demonstrated that miR-200a-3p post-transcriptionally regulates CRMP1 and stimulates the proliferation of human EC cells.
The recognition of the differential regulation and function of CRMP1 in EC will ultimately provide a better understanding of the signaling pathways that can be therapeutically modulated. We have merely just begun to explore the role of miR-200a-3p in EC.
